IKNA insider filings
ImageneBio, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2025-07-30. Screen IKNA transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for IKNA between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — ImageneBio, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-07-30 | 4 | ORBIMED ADVISORS LLC — Director OrbiMed Capital GP VI LLC — Director OrbiMed Genesis GP LLC — Director | Grant/award (A): 83,611 @ $2.49 | EDGAR |
| 2024-06-10 | 4 | Koehler Maria — Director | Grant/award (A): 17,520 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Wooster Richard — Director | Grant/award (A): 17,520 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Dukes Iain D. — Director | Grant/award (A): 17,520 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Hughes Owen — Director | Grant/award (A): 17,520 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Bonita David P — Director | Grant/award (A): 17,520 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Stampacchia Otello — Director | Grant/award (A): 17,520 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | FORMELA JEAN FRANCOIS — Director | Grant/award (A): 17,520 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | Germa Caroline — Chief Medical Officer | Grant/award (A): 579,100 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | Ecsedy Jeffrey — Chief Development Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | Manfredi Mark — President & CEO, Director | Grant/award (A): 320,000 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | Marango Jotin — CFO & Head of Corp. Dev. | Grant/award (A): 181,000 (derivative) @ $0 | EDGAR |
| 2023-09-21 | 4/A | Bonita David P — Director | Grant/award (A): 153,121 · Grant/award (A): 353,192 (derivative) | EDGAR |
| 2023-09-21 | 4/A | ORBIMED ADVISORS LLC — Director OrbiMed Capital GP VI LLC — Director OrbiMed Genesis GP LLC — Director | Grant/award (A): 153,121 · Grant/award (A): 353,192 (derivative) | EDGAR |
| 2023-09-14 | 4 | Bonita David P — Director | Grant/award (A): 153,121 · Grant/award (A): 353,192 (derivative) | EDGAR |
| 2023-09-14 | 4 | ORBIMED ADVISORS LLC — Director OrbiMed Capital GP VI LLC — Director OrbiMed Genesis GP LLC — Director | Grant/award (A): 153,121 · Grant/award (A): 353,192 (derivative) | EDGAR |
| 2023-06-13 | 4 | Koehler Maria — Director | Grant/award (A): 17,520 (derivative) @ $0 | EDGAR |
| 2023-06-13 | 4 | Wooster Richard — Director | Grant/award (A): 17,520 (derivative) @ $0 | EDGAR |
| 2023-06-13 | 4 | Dukes Iain D. — Director | Grant/award (A): 17,520 (derivative) @ $0 | EDGAR |
| 2023-06-13 | 4 | Hughes Owen — Director | Grant/award (A): 17,520 (derivative) @ $0 | EDGAR |
| 2023-06-13 | 4 | Bonita David P — Director | Grant/award (A): 17,520 (derivative) @ $0 | EDGAR |
| 2023-06-13 | 4 | Stampacchia Otello — Director | Grant/award (A): 17,520 (derivative) @ $0 | EDGAR |
| 2023-06-13 | 4 | FORMELA JEAN FRANCOIS — Director | Grant/award (A): 17,520 (derivative) @ $0 | EDGAR |
| 2023-01-05 | 4 | Ecsedy Jeffrey — Chief Development Officer | Grant/award (A): 105,000 (derivative) @ $0 | EDGAR |
| 2023-01-05 | 4 | Zhang Xiaoyan Michelle — Chief Scientific Officer | Grant/award (A): 105,000 (derivative) @ $0 | EDGAR |
| 2023-01-05 | 4 | Manfredi Mark — President & CEO, Director | Grant/award (A): 220,000 (derivative) @ $0 | EDGAR |
| 2023-01-05 | 4 | Marango Jotin — CFO & Head of Corp. Dev. | Grant/award (A): 105,000 (derivative) @ $0 | EDGAR |
| 2023-01-05 | 4 | Santillana Sergio L. — Chief Medical Officer | Grant/award (A): 105,000 (derivative) @ $0 | EDGAR |
| 2022-12-19 | 4 | Hughes Owen — Director | Grant/award (A): 35,040 (derivative) @ $0 | EDGAR |
| 2022-06-24 | 4 | Bonita David P — Director | Purchase (P): 66,806 @ $3.55 · Purchase (P): 23,419 @ $3.71 · Purchase (P): 65,965 @ $4.37 · Purchase (P): 96,035 @ $5.37 | EDGAR |
| 2022-06-24 | 4 | ORBIMED ADVISORS LLC — Director OrbiMed Capital GP VI LLC — Director OrbiMed Genesis GP LLC — Director | Purchase (P): 66,806 @ $3.55 · Purchase (P): 23,419 @ $3.71 · Purchase (P): 65,965 @ $4.37 · Purchase (P): 96,035 @ $5.37 | EDGAR |
| 2022-06-13 | 4 | Koehler Maria — Director | Grant/award (A): 13,419 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | Wooster Richard — Director | Grant/award (A): 13,419 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | Dukes Iain D. — Director | Grant/award (A): 13,419 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | Bonita David P — Director | Grant/award (A): 13,419 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | Stampacchia Otello — Director | Grant/award (A): 13,419 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | Renaud Ronald C JR — Director | Grant/award (A): 13,419 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | FORMELA JEAN FRANCOIS — Director | Grant/award (A): 13,419 (derivative) @ $0 | EDGAR |
| 2022-04-25 | 4 | Marango Jotin — CFO & Head of Corp. Dev. | Grant/award (A): 397,199 (derivative) @ $0 | EDGAR |
| 2022-02-04 | 4 | Zhang Xiaoyan Michelle — Chief Scientific Officer | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2022-02-04 | 4 | Manfredi Mark — President & CEO, Director | Grant/award (A): 238,900 (derivative) @ $0 | EDGAR |
| 2022-02-04 | 4 | Ecsedy Jeffrey — Chief Development Officer | Grant/award (A): 59,360 (derivative) @ $0 | EDGAR |
| 2022-02-04 | 4 | Tessier Maude — Chief Business Officer | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2022-02-04 | 4 | Santillana Sergio L. — Chief Medical Officer | Grant/award (A): 70,400 (derivative) @ $0 | EDGAR |
| 2022-01-25 | 4 | Wooster Richard — Director | Grant/award (A): 29,200 (derivative) @ $0 | EDGAR |
| 2022-01-20 | 4 | Tessier Maude — Chief Business Officer | Option exercise (M): 38,915 @ $2.94 · Option exercise (M): 24,606 @ $4.15 · Option exercise (M): 8,265 @ $4.51 · Option exercise (M): 38,915 (derivative) @ $0 · Option exercise (M): 24,606 (derivative) @ $0 · Option exercise (M): 8,265 (derivative) @ $0 | EDGAR |
| 2022-01-12 | 4 | Zhang Xiaoyan Michelle — Chief Scientific Officer | Option exercise (M): 36 @ $2.15 · Sale (S): 36 @ $12 · Option exercise (M): 964 @ $2.15 · Sale (S): 964 @ $12 · Option exercise (M): 36 (derivative) @ $0 · Option exercise (M): 964 (derivative) @ $0 | EDGAR |
| 2021-12-23 | 4 | Stampacchia Otello — Director | Grant/award (A): 13,419 (derivative) @ $0 | EDGAR |
| 2021-12-23 | 4 | Renaud Ronald C JR — Director | Grant/award (A): 13,419 (derivative) @ $0 | EDGAR |
| 2021-12-23 | 4 | FORMELA JEAN FRANCOIS — Director | Grant/award (A): 13,419 (derivative) @ $0 | EDGAR |
Recent 8-K events — ImageneBio, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-09 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-23 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-26 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-17 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-17 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-17 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=IKNA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs